Guizhou Yibai Pharmaceutical Co Ltd (600594) — Tangible Net Worth Ratio
Guizhou Yibai Pharmaceutical Co Ltd (600594) has a Tangible Net Worth Ratio of 86.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥308.26 Million) from net assets (CN¥2.24 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Guizhou Yibai Pharmaceutical Co Ltd (600594) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Guizhou Yibai Pharmaceutical Co Ltd Tangible Net Worth Ratio (2001–2025)
This chart shows how Guizhou Yibai Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 25 annual periods from 2001 to 2025. As of March 2026, the ratio stands at 86.2%, reflecting net assets of CN¥2.24 Billion with intangible assets of CN¥308.26 Million CNY. See Guizhou Yibai Pharmaceutical Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Guizhou Yibai Pharmaceutical Co Ltd (2001–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Guizhou Yibai Pharmaceutical Co Ltd from 2001 to 2025, covering 25 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Guizhou Yibai Pharmaceutical Co Ltd market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 86.2% | CN¥2.27 Billion | CN¥312.29 Million | CN¥3.44 Billion | ▼ -1.5 pp |
| 2024 | 87.7% | CN¥2.61 Billion | CN¥319.56 Million | CN¥4.10 Billion | ▼ -1.3 pp |
| 2023 | 89.0% | CN¥3.02 Billion | CN¥330.89 Million | CN¥4.60 Billion | ▲ +0.4 pp |
| 2022 | 88.7% | CN¥3.19 Billion | CN¥362.03 Million | CN¥4.87 Billion | ▼ -0.7 pp |
| 2021 | 89.4% | CN¥3.56 Billion | CN¥378.54 Million | CN¥5.07 Billion | ▼ -0.8 pp |
| 2020 | 90.1% | CN¥3.46 Billion | CN¥341.97 Million | CN¥5.23 Billion | ▲ +0.7 pp |
| 2019 | 89.4% | CN¥3.72 Billion | CN¥393.59 Million | CN¥5.62 Billion | ▼ -1.2 pp |
| 2018 | 90.6% | CN¥3.91 Billion | CN¥367.99 Million | CN¥6.48 Billion | ▼ -1.7 pp |
| 2017 | 92.3% | CN¥4.64 Billion | CN¥357.14 Million | CN¥7.19 Billion | ▲ +1.1 pp |
| 2016 | 91.2% | CN¥4.19 Billion | CN¥367.40 Million | CN¥6.59 Billion | ▲ +1.2 pp |
| 2015 | 90.1% | CN¥3.55 Billion | CN¥352.78 Million | CN¥5.59 Billion | ▲ +1.0 pp |
| 2014 | 89.1% | CN¥3.42 Billion | CN¥374.58 Million | CN¥5.50 Billion | ▼ -6.0 pp |
| 2013 | 95.1% | CN¥1.93 Billion | CN¥95.00 Million | CN¥3.20 Billion | ▲ +3.8 pp |
| 2012 | 91.3% | CN¥1.55 Billion | CN¥134.57 Million | CN¥2.28 Billion | ▲ +4.9 pp |
| 2011 | 86.4% | CN¥1.14 Billion | CN¥155.22 Million | CN¥1.80 Billion | ▲ +0.3 pp |
| 2010 | 86.1% | CN¥876.05 Million | CN¥121.88 Million | CN¥1.56 Billion | ▲ +0.8 pp |
| 2009 | 85.3% | CN¥710.95 Million | CN¥104.64 Million | CN¥1.28 Billion | ▲ +8.0 pp |
| 2008 | 77.3% | CN¥598.16 Million | CN¥135.89 Million | CN¥1.22 Billion | ▲ +1.1 pp |
| 2007 | 76.2% | CN¥530.04 Million | CN¥126.22 Million | CN¥1.14 Billion | ▼ -4.4 pp |
| 2006 | 80.6% | CN¥425.69 Million | CN¥82.75 Million | CN¥987.97 Million | ▼ -12.6 pp |
| 2005 | 93.2% | CN¥547.39 Million | CN¥37.35 Million | CN¥1.20 Billion | ▼ -3.3 pp |
| 2004 | 96.5% | CN¥506.70 Million | CN¥17.63 Million | CN¥867.80 Million | ▲ +5.0 pp |
| 2003 | 91.5% | CN¥180.22 Million | CN¥15.36 Million | CN¥455.14 Million | ▼ -6.4 pp |
| 2002 | 97.9% | CN¥128.20 Million | CN¥2.72 Million | CN¥303.07 Million | ▲ +1.2 pp |
| 2001 | 96.6% | CN¥82.63 Million | CN¥2.78 Million | CN¥217.81 Million | — |